Adjuvant Pembrolizumab Improved Distant Metastasis-Free Survival in Resected Stage IIB, IIC Melanoma
Pembrolizumab significantly improved distant metastasis-free survival and reduced recurrence in stage IIB and IIC melanoma.
Immunotherapy
Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Bacterial Supplement May Improve CPI Outcomes in Metastatic Kidney Cancer
In a phase 1 trial, investigators tested whether an oral supplement containing a strain of Clostridium butyricum increases the abundance of certain gut bacteria known to be associated with a better response to immune checkpoint inhibitors.
Bladder Cancer Progression Despite BCG Therapy Predicts Worse Outcomes
Progression on bacillus Calmette-Guérin (BCG) likely represents a biologically aggressive disease state as well as diagnostic delay, according to investigators.
First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival
Real-world data validate recently reported findings from clinical trials.
Second-Line Immunotherapy May Improve Survival in Mesothelioma
Immune checkpoint inhibitors prolonged survival when compared with chemotherapy.
Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors
Response endpoints were not strongly correlated with overall survival at the trial level.
No Benefit With Ipilimumab Plus Nivolumab in Previously Treated Squamous Non-Small Cell Lung Cancer
There was no improvement in progression-free or overall survival.
Can Patients With Multiple Myeloma Boost Their Immunity?
Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...